JP2004536825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536825A5 JP2004536825A5 JP2003506641A JP2003506641A JP2004536825A5 JP 2004536825 A5 JP2004536825 A5 JP 2004536825A5 JP 2003506641 A JP2003506641 A JP 2003506641A JP 2003506641 A JP2003506641 A JP 2003506641A JP 2004536825 A5 JP2004536825 A5 JP 2004536825A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- modified pectin
- medicament
- galectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 21
- 229920001277 pectin Polymers 0.000 description 18
- 235000010987 pectin Nutrition 0.000 description 18
- 239000001814 pectin Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 11
- 102000007563 Galectins Human genes 0.000 description 6
- 108010046569 Galectins Proteins 0.000 description 6
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- 229920002230 Pectic acid Polymers 0.000 description 4
- 239000010318 polygalacturonic acid Substances 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 102000000795 Galectin 1 Human genes 0.000 description 2
- 108010001498 Galectin 1 Proteins 0.000 description 2
- 102000000802 Galectin 3 Human genes 0.000 description 2
- 108010001517 Galectin 3 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30036001P | 2001-06-22 | 2001-06-22 | |
| US10/176,022 US20030004132A1 (en) | 2001-06-22 | 2002-06-20 | Method and material for treating immune diseases |
| PCT/US2002/019886 WO2003000195A2 (en) | 2001-06-22 | 2002-06-21 | Method and material for treating immune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536825A JP2004536825A (ja) | 2004-12-09 |
| JP2004536825A5 true JP2004536825A5 (enExample) | 2006-01-05 |
Family
ID=26871794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506641A Pending JP2004536825A (ja) | 2001-06-22 | 2002-06-21 | 免疫疾患を治療する方法及び物質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030004132A1 (enExample) |
| EP (1) | EP1408989A2 (enExample) |
| JP (1) | JP2004536825A (enExample) |
| CN (1) | CN100558368C (enExample) |
| BR (1) | BR0210547A (enExample) |
| CA (1) | CA2451885A1 (enExample) |
| IL (1) | IL159462A0 (enExample) |
| WO (1) | WO2003000195A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1980257A1 (en) | 2003-04-07 | 2008-10-15 | Prospect Therapeutics, Inc. | Compositions and uses of galectin antagonists |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2005058352A2 (en) * | 2003-12-17 | 2005-06-30 | Entelos, Inc. | Treatment of rheumatoid arthritis with galectin-3 antagonists |
| EP1765874A1 (en) | 2004-03-26 | 2007-03-28 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| CN104245717B (zh) | 2011-12-28 | 2017-10-24 | 卡莱克汀医疗有限公司 | 用于治疗人类疾病的新型糖类药物的组合物 |
| WO2013184892A1 (en) * | 2012-06-06 | 2013-12-12 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
| JP6415437B2 (ja) | 2012-09-17 | 2018-10-31 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 癌の処置における特異的免疫療法を向上する方法 |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| JP2016507503A (ja) | 2012-12-20 | 2016-03-10 | ヘンリー フォード ヘルス システム | ガレクチン−３を阻害することによる拡張期心不全を治療する方法 |
| US12390486B2 (en) | 2012-12-20 | 2025-08-19 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA3088736A1 (en) * | 2018-01-21 | 2019-07-25 | Rensselaer Polytechnic Institute | Method of treating galectin-3 dependent disorders |
| CA3102155A1 (en) | 2018-06-29 | 2020-01-02 | Glykos Biomedical Oy | Conjugates |
| US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| WO1992000310A1 (en) * | 1990-06-27 | 1992-01-09 | Dainippon Ink & Chemicals, Inc. | Alkylated oligosaccharide and acetyl derivative thereof |
| US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
| CA2279791C (en) * | 1998-08-14 | 2011-11-08 | Marcus B. Gohlke | Dietary supplement combining colostrum and lactorferrin in a mucosal delivery format |
| US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
-
2002
- 2002-06-20 US US10/176,022 patent/US20030004132A1/en not_active Abandoned
- 2002-06-21 CA CA002451885A patent/CA2451885A1/en not_active Abandoned
- 2002-06-21 EP EP02749642A patent/EP1408989A2/en not_active Withdrawn
- 2002-06-21 CN CNB028160916A patent/CN100558368C/zh not_active Expired - Fee Related
- 2002-06-21 JP JP2003506641A patent/JP2004536825A/ja active Pending
- 2002-06-21 WO PCT/US2002/019886 patent/WO2003000195A2/en not_active Ceased
- 2002-06-21 IL IL15946202A patent/IL159462A0/xx unknown
- 2002-06-21 BR BR0210547-0A patent/BR0210547A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004535430A5 (enExample) | ||
| Donaruma | Synthetic biologically active polymers | |
| JP4965043B2 (ja) | 抗癒着性炭水化物 | |
| Yilmaz | Chitosan: a versatile biomaterial | |
| JP2003522732A5 (enExample) | ||
| CA2626398A1 (en) | Dietary fiber formulation and method of administration | |
| UA89791C2 (ru) | Пищевая композиция, которая содержит неусваиваемые олигосахариды, для лечения или профилактики инфекций респираторного тракта | |
| CA2326510A1 (en) | Dextran formulations and method for treatment of inflammatory joint disorders | |
| WO2003008618A3 (en) | Glucans and glucansucrases derived from lactic acid bacteria | |
| Mudgal et al. | Immunomodulatory role of chitosan‐based nanoparticles and oligosaccharides in cyclophosphamide‐treated mice | |
| WO2006059029A3 (fr) | Solutions viscoelastiques renfermant du hyaluronate de sodium et de l'hydroxypropylmethyl- cellulose, preparation et utilisations | |
| WO2004032849A3 (en) | Methods of administering fgf18 | |
| SI2099462T1 (sl) | Farmacevtski pripravek za zdravljenje vnetnih bolezni urogenitalnega trakta | |
| JP2006516988A (ja) | 持続した薬物放出またはムコ粘着のための活性剤およびキトサンを含む製薬組成物 | |
| WO2004098564A3 (en) | Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide | |
| CA2519797A1 (en) | Low molecular weight hyaluronic acid for the treatment of nerve damage | |
| EP1408989A2 (en) | Method and material for treating immune diseases | |
| WO2005027951B1 (en) | Method for controlling angiogenesis in animals | |
| WO2004012652A3 (en) | Treatment of multiple sclerosis with brain targeted anti oxidant compounds | |
| WO2003094842A3 (en) | Conjugates comprising central nervous system active drug | |
| EP1561760A3 (en) | Low molecular weight heparin salt with thriethanolamine | |
| CN108383224A (zh) | 一种绿色环保除菌的絮凝剂 | |
| CA2489862C (en) | Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation | |
| US8871740B2 (en) | Use of polysaccharides for treating stress and anxiety | |
| Singh et al. | Chitosan hydrogel: Its applications in medicine and dentistry |